Turkmenistan Medical Device Registration Fees and Budget Planning
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The cost of device registration in Turkmenistan consists of at least 3 components:
- State fees for national registration — paid in accordance with notices of the competent authority;
- Mandatory certification fees (TDS) — conformity assessment fees under the Law on Certification;
- Document chain costs — notarization, consular legalization and translation.
Key notice: this verification round did not obtain the original official fee schedule of Turkmenistan. This document therefore states no specific amounts; all amounts are handled as practical estimates and must be confirmed case by case with the competent authority or the local representative. Because no official fee schedule was located, the budget must be built as ranges confirmed case by case, not as fixed line items copied from other markets.
2. Legal basis
| Legal instrument | Reference / number | Publication date | Provisions |
|---|---|---|---|
| Law of Turkmenistan on Drug Provision | No. 319-V | January 12, 2016 | National registration procedure and state fees (paid in accordance with notices of the competent authority) |
| Law of Turkmenistan on Certification | No public number (law) | Current version | Mandatory certification of imported products (TDS) and the associated fees |
| Hague Convention Abolishing Legalization of 1961 | None (international convention) | Member list, January 2025 edition | Turkmenistan is not a member; documents require consular legalization |
3. Expert insights
Insight 1: state fees are triggered by notice, not by a published price list.
The regime statements show that the state fee is paid only after expert review is completed and an invoice is issued, rather than being paid in a lump sum at submission. This means the fee amount is determined case by case by the competent authority, and companies cannot look up accurate figures from public sources at the project initiation stage. The invoice stage should therefore be treated as a scheduled milestone in the project plan, with a payment path prepared in advance.
Insight 2: state fees are generally non-refundable.
Industry sources consistently state that fees are not refunded when registration is refused. Combined with the unpredictability of the amounts, this means the financial risk of a Turkmenistan project is higher than in markets with published fee schedules, and the budget should include the possibility of a resubmission. A refused application carries the full cost of the first attempt, which strengthens the case for a thorough pre-submission review.
Insight 3: document chain costs are disproportionately high in this market.
Because Turkmenistan is not a member of the Hague Convention Abolishing Legalization (Article 15 of this series), every foreign document must pass through the full chain of notarization, then Ministry of Justice legalization, then Ministry of Foreign Affairs legalization, then embassy or consulate legalization. This process is charged per document and measured in weeks, and in projects with many models and many documents it becomes a significant cost item. For a typical registration file the chain runs across notarization, two ministries and a consulate, and any single defective document restarts its own chain.
Insight 4: payment time counts toward the project period and is excluded from the 180 days.
As explained in Article 09, the 180 days do not include the time for fee payment. Consequently, the speed of payment directly affects the project period — unlike in most markets, where payment is merely an administrative step. Setting a standing payment arrangement with the local representative is the common mitigation.
Insight 5: TDS certification fees and registration state fees are two separate budget lines.
Mandatory certification (TDS) is charged independently by the national standards system and belongs to a separate system from the national registration state fees. The most common corporate error is to budget only for the registration fee and to omit the certification fee and sample testing costs. Where local testing is required, the sample testing charges belong to the certification side of the budget as well.
4. Practical recommendations
- Model the budget in three separate blocks — registration state fees, TDS certification fees and document chain costs; do not merge the estimates.
- Treat all amounts as subject to current notices of the competent authority, and reserve ranges as practical estimates at the project initiation stage.
- Include the possibility of resubmission in the budget, because state fees are generally non-refundable.
- Estimate document chain costs item by item per document, and reserve for at least one round of rework.
- Preset a fast track for fee payment, so that payment does not stretch the project period.
5. Verification checklist
- □ The budget is modeled in three separate blocks (state fees / certification fees / document chain).
- □ Amounts are marked as practical estimates and subject to current notices.
- □ The budget includes the possibility of resubmission.
- □ Document chain costs are estimated item by item by number of documents.
- □ A fast track for fee payment has been preset.
Regulatory information verified as of October 30, 2026. The content cited in this document was checked against the provisions of Law No. 319-V on Drug Provision (January 12, 2016) on state fees for national registration paid in accordance with notices of the competent authority, and against the mandatory certification regime of the Law on Certification; this round did not obtain the original official fee schedule of Turkmenistan, no specific amounts are stated, and all amounts are handled as practical estimates; the statement that state fees are non-refundable comes from industry sources and must be confirmed case by case.
GRZAN support in Turkmenistan: GRZAN provides registration support to manufacturers, importers and authorized representatives for this market. Local resources can be coordinated, including licensed importing entities and authorized representative arrangements, covering national registration submission, the consular legalization chain for documents, delivery of samples, alignment with mandatory TDS certification, and customs clearance support. Service capabilities include classification judgment, selection of the registration pathway, preparation of dossiers in the national format, notarization and consular legalization, preparation of testing and stability documentation, organization of GMP and ISO 13485 evidence, variations and renewal, and vigilance and post-market maintenance. Contact: info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us